Before even going into Phase II trials, Theravance Biopharma Inc. has bagged the biggest player in inflammatory bowel disease – Johnson & Johnson – as a partner for its pan-Janus kinase (JAK) inhibitor which the firm is already talking about as a transformational treatment for ulcerative colitis and Crohn's disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?